We are live on ! Find out more
BC

Birchview Capital Portfolio holdings

AUM $176M
1-Year Est. Return 95.04%
This Fund
S&P 500
This Quarter Est. Return
+7.33%
1 Year Est. Return
+95.04%
3 Year Est. Return
+233.14%
5 Year Est. Return
+280.2%
10 Year Est. Return
+1,023.63%
AUM
$123M
AUM Growth
+$7.42M
Cap. Flow
+$6.34M
Cap. Flow %
5.16%
Top 10 Hldgs %
65.43%
Holding
71
New
10
Increased
12
Reduced
8
Closed
3

Top Buys

Rank Stock Value
1
TECL icon
Direxion Daily Technology Bull 3x ETF
TECL
+$1.68M
2
PRTA icon
Prothena Corp
PRTA
+$1.5M
3
DCGO icon
DocGo
DCGO
+$960K
4
RARE icon
Ultragenyx Pharmaceutical
RARE
+$794K
5
TMCI icon
Treace Medical Concepts
TMCI
+$622K

Top Sells

Rank Stock Value
1
ATEC icon
Alphatec Holdings
ATEC
+$1.12M
2
ACAD icon
Acadia Pharmaceuticals
ACAD
+$1M
3
ELUT icon
Elutia
ELUT
+$371K
4
PGNY icon
Progyny
PGNY
+$369K
5
CHRS icon
Coherus Oncology
CHRS
+$325K

Sector Composition

Rank Sector Weight
1 Healthcare 96.88%
2 Energy 3.02%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
BMY icon
1
Bristol-Myers Squibb
BMY
$124B
$38.8M 31.53%
685,182
-1,000
-0.1% -$55.9K
BDSX icon
2
Biodesix
BDSX
$209M
$8.78M 7.14%
286,806
+2,000
+0.7% +$58.8K
ACAD icon
3
Acadia Pharmaceuticals
ACAD
$4.38B
$6.21M 5.05%
338,400
-62,000
-15% -$1M
ELUT icon
4
Elutia
ELUT
$42M
$4.58M 3.73%
1,225,489
-95,726
-7% -$371K
PRTA icon
5
Prothena Corp
PRTA
$453M
$4.22M 3.43%
304,574
+95,000
+45% +$1.5M
NBIX icon
6
Neurocrine Biosciences
NBIX
$17.2B
$4.13M 3.36%
30,240
– –
CORT icon
7
Corcept Therapeutics
CORT
$9.72B
$3.73M 3.03%
74,000
– –
UTHR icon
8
United Therapeutics
UTHR
$22.7B
$3.53M 2.87%
10,000
– –
AXGN icon
9
Axogen
AXGN
$2.12B
$3.25M 2.64%
197,000
– –
DCGO icon
10
DocGo
DCGO
$64.3M
$3.24M 2.64%
764,062
+249,062
+48% +$960K
QDEL icon
11
QuidelOrtho
QDEL
$1.19B
$3.01M 2.45%
67,619
– –
PHR icon
12
Phreesia
PHR
$662M
$2.89M 2.35%
114,700
– –
TVTX icon
13
Travere Therapeutics
TVTX
$5.27B
$2.58M 2.1%
148,000
– –
MASI
14
DELISTED
Masimo
MASI
$2.53M 2.06%
15,280
– –
HROW icon
15
Harrow
HROW
$1.74B
$2.45M 1.99%
72,910
– –
STOK icon
16
Stoke Therapeutics
STOK
$1.81B
$2.32M 1.88%
210,000
– –
OVV icon
17
Ovintiv
OVV
$16.2B
$2.11M 1.72%
52,200
– –
CSTL icon
18
Castle Biosciences
CSTL
$733M
$2.08M 1.69%
78,000
+20,000
+34% +$609K
PTGX icon
19
Protagonist Therapeutics
PTGX
$9.06B
$1.85M 1.51%
48,000
– –
EQT icon
20
EQT Corp
EQT
$31B
$1.6M 1.3%
34,619
– –
FHTX icon
21
Foghorn Therapeutics
FHTX
$305M
$1.47M 1.19%
310,930
-10,000
-3% -$72.8K
ALKS icon
22
Alkermes
ALKS
$8.79B
$1.44M 1.17%
50,000
– –
TMCI icon
23
Treace Medical Concepts
TMCI
$279M
$1.2M 0.98%
161,350
+93,000
+136% +$622K
NVCR icon
24
NovoCure
NVCR
$1.84B
$924K 0.75%
31,000
+11,000
+55% +$233K
TXG icon
25
10x Genomics
TXG
$5.55B
$718K 0.58%
50,000
+20,000
+67% +$316K
1
2 3

Similar funds

RWA
Resolute Wealth Advisor Findlay, Ohio $176M AUM
BAM
Boyar Asset Management New York $176M AUM 20.04% 1-Year Est. Return
TIM
Tevis Investment Management Plano, Texas $176M AUM 18.14% 1-Year Est. Return
TFCM
Taylor Frigon Capital Management Scottsdale, Arizona $176M AUM 24.25% 1-Year Est. Return
FPW
Flywheel Private Wealth Los Altos, California $176M AUM 26.12% 1-Year Est. Return
LWM
Lifetime Wealth Management Rockwall, Texas $176M AUM
PFA
Providence Financial Advisors Overland Park, Kansas $175M AUM
DAM
Draper Asset Management Smithtown, New York $176M AUM 37.45% 1-Year Est. Return

Birchview Capital's Q4 2024 Portfolio in Review

As of Q4 2024, Birchview Capital held 71 positions worth $123M, up 6.4% from $115M the previous quarter. Its ten largest holdings account for 65% of the portfolio.

Birchview Capital deployed $6.34M of net new capital in Q4 2024, opening 10 new positions and adding to 12 existing holdings. Its largest new stake was Direxion Daily Technology Bull 3x ETF: 18,000 shares worth $128K.

By sector, the portfolio is most concentrated in Healthcare at 97% of assets, down from 97% a quarter earlier, followed by Energy.

On the sell side, the largest reduction was Alphatec Holdings, an estimated $1.12M trimmed.

  • Birchview Capital's largest Q4 2024 buy was Direxion Daily Technology Bull 3x ETF: 18,000 shares worth $128K.
  • Birchview Capital added most to Prothena Corp in Q4 2024, an estimated $1.5M increase.
  • Birchview Capital's biggest Q4 2024 reduction was Alphatec Holdings, cutting an estimated $1.12M.
  • Birchview Capital fully exited Progyny in Q4 2024, selling an estimated $369K.
  • Birchview Capital's ten largest holdings make up 65% of its $123M portfolio in Q4 2024.
  • Birchview Capital opened 10 new positions and closed 3 in Q4 2024.
  • Birchview Capital's portfolio value rose 6.4% quarter-over-quarter to $123M.

Based on Birchview Capital's 13F filing for Q4 2024, filed 14 Feb 2025.